Shanghai Shenqi Pharmaceutical Investment Management Third Quarter 2024 Earnings: EPS: CN¥0.04 (vs CN¥0.064 in 3Q 2023)

Shanghai Shenqi Pharmaceutical Investment Management (SHSE:600613) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥452.9m (down 10% from 3Q 2023).
• Net income: CN¥21.5m (down 31% from 3Q 2023).
• Profit margin: 4.8% (down from 6.2% in 3Q 2023).
• EPS: CN¥0.04 (down from CN¥0.064 in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai Shenqi Pharmaceutical Investment Management shares are up 22% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for Shanghai Shenqi Pharmaceutical Investment Management that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.